Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SAT1 | P21673 | 3/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12380893 | 0.91 | CYP2C19 (0.48) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL18859432 | 0.85 | CYP2C19 (0.39) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL15510820 | 0.84 | TSHR (0.40) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL24240115 | 0.80 | KDM4E (0.42) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL26503335 | 0.80 | CYP2C19 (0.37) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL22317388 | 0.79 | CA12 (0.48) | CYP2C19MEN1KMT2ATSHRCYP1A2 | |
| SCHEMBL23098371 | 0.79 | — | — | |
| SCHEMBL12262494 | 0.78 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11452942 | 0.77 | ALDH1A1 (0.41) | CYP2C19MEN1KMT2ATSHRCYP1A2 | |
| SCHEMBL26503331 | 0.77 | DRD2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2021-07-01 | — | — | US | disclosed |
| EP-2708529-B1 | METHOD FOR MANUFACTURING PARTICLES | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9796831-B2 | Process for producing particles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170042989-A1 | PHOTOSENSITIZED TRYPANOSOMATIDS AND VACCINE COMPOSITIONS THEREOF | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 2017-02-16 | — | — | US | disclosed |
| CN-103974929-B | The manufacture method of the halogen acid salt of haloalkylamine | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| CN-103534236-B | Method for producing granules | 住友化学株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-103974929-A | Method for producing hydrohalic acid salt of halogenated alkyl amine | SUMITOMO CHEMICAL CO | 2014-08-06 | — | — | CN | disclosed |
| EP-2708529-A1 | METHOD FOR MANUFACTURING PARTICLES | Sumitomo Chemical Company Limited (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20140065337-A1 | PROCESS FOR PRODUCING PARTICLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| CN-103534236-A | Method for producing granules | SUMITOMO CHEMICAL CO | 2014-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | CYP2C19 4251/4885MEN1 2766/4885GLA 2070/4885 |
| US-20170042989-A1 | PHOTOSENSITIZED TRYPANOSOMATIDS AND VACCINE COMPOSITIONS THEREOF | CD47, TAP1, TAP2 | CYP2C19 4361/4885MEN1 430/4885GLA 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.